The spectrum of Ergoferon pharmacological activity includes antiviral, immunomodulatory, antihistamine, anti-inflammatory.
The effectiveness of Ergoferon components for viral infectious diseases has been experimentally and clinically proved: influenza A and influenza B, acute respiratory viral infections (caused by parainfluenza viruses, adenoviruses, respiratory syncytial viruses, coronaviruses), herpesvirus infections (labial herpes, ophthalmoherpes, genital herpes, herpes zoster, Chicken pox, infectious mononucleosis), acute intestinal infections of viral etiology (caused by caliciviruses, coronaviruses, rotaviruses, enteroviruses), enteroviral and meningococcal meningitis, hemorrhagic fever with renal syndrome, encephalitis.
Ergoferon is used in combination therapy of bacterial infections (pseudotuberculosis, whooping cough, yersiniosis, pneumonia of various etiologies including atypical pathogens (M. pneumoniae, C. Pneumoniae, Legionella spp), is used for prevention of bacterial complications of viral infections, prevents the development of superinfections. The usage of Ergoferon during pre- and post-vaccination period increases the effectiveness of vaccination, provides non-specific prophylaxis of ARVI and flu in the period of post-vaccination immunity establishment. Ergoferon possesses prophylactic effectiveness against acute respiratory viral infections of non-flu etiology, prevents the development of intercurrent diseases in postvaccination period.
Components of Ergoferon possess the same mechanism of action as activation of functional activity of CD4 receptor, receptors to interferon gamma (IFN-γ) and histamine, correspondingly accompanied by pronounced immunotropic action.
It was experimentally proved that antibodies to interferon gamma:
increase expression of IFN-γ, IFN α/β and associated interleukins (IL-2, IL-4, IL-10 and others).), improve ligand-receptor interaction of IFN, restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFN-γ, which is an important factor in the natural antiviral tolerance of the body; stimulate interferon-dependent biological processes: induction of expression of antigens of the main histocompatibility complex of types I, II and Fc-receptors, monocyte activation, stimulation of functional activity of NK-cells, regulation of immunoglobulin synthesis, activating mixed Th1 and Th2 immune response.
Antibodies to CD4, being probably allosteric modulators of the receptor, regulate functional activity of CD4 receptor that results in increase of functional activity of CD4 lymphocytes, normalization of immunoregulatory index CD4/CD8 as well as subpopulation structure of immunocompetent cells (CD3, CD4, CD8, CD16, CD20).
. Antibodies to histamine modify histamine-dependent activation of peripheral and central H1-receptors, thus reducing tone of bronchial smooth muscle and capillary permeability that results in reduction of duration and severity of rhinorrhea, nasal mucous membrane edema, cough and sneezing,
Allergic reactions accompanying infectious process decrease due to suppression of histamine release from mast cells and basophils, leukotrienes production, adhesion molecules synthesis, decrease of eosinophils chemotaxis and platelet aggregation in reactions to contact with allergen.
Combined use of components of Ergoferon complex preparation is accompanied by enhanced antiviral activity of its components.
Runny nose (rhinitis), Colds, Headache, Herpes, whooping cough, Raised body temperature, Prevention of flu and colds, Chills, Flu, Edema Ergoferon is indicated for use in adults and children aged 6 months and older.
Treatment of influenza and acute respiratory viral infections (ARI).
Treatment of acute intestinal infections of viral etiology.
Per 1 tablet:
antibodies to human gamma interferon affinity purified – 0.006 g*,
Antibodies to histamine affinity purified – 0,006 g*,
antibodies to CD4 affinity purified – 0,006 g*
Excipients: 0.267 g lactose monohydrate, 0.03 g microcrystalline cellulose, 0.003 g magnesium stearate.
* applied to lactose monohydrate as a mixture of three active aqueous-alcoholic dilutions of the substance, diluted respectively 100 12, 100 30, 100 50 times.
How to take, the dosage
Risk is not intended to divide the tablet into parts.
Orally, not with meals. The tablet should be kept in the mouth without swallowing until the complete dissolution.
When administering the drug to young children (from 6 months to 3 years) it is recommended to dissolve the tablet in a small amount (1 tablespoon) of boiled water at room temperature.
Adults and children from 6 months.
On the 1st day of treatment 8 tablets are taken under the following scheme: 1 tablet every 30 minutes during the first 2 hours (5 tablets in 2 hours in total). On the 2nd day and further 1 tablet 3 times at regular intervals is taken during the same day.
On the 2nd day and further 1 tablet 3 times a day until the complete recovery.
Incompatibilities with other medications have not been reported to date.
The drug contains lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or in patients with congenital lactase deficiency.
Tablets are flat-cylindrical with a rib and bevel, white to almost white.
On the flat side with a rib there is the inscription MATERIA MEDICA, on the other flat side there is the inscription ERGOFERON.
Increased individual sensitivity to the drug components.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Children under 6 months.
Individual hypersensitivity reactions to the drug components are possible.
In an accidental overdose, dyspepsia is possible due to the excipients in the drug.
The safety of the drug Ergoferon in pregnant women has not been studied.
During pregnancy and lactation the drug is used only if the estimated benefits to the mother exceed the potential risk to the fetus and child.
The ratio “benefit-risk” is determined by the attending physician. If necessary, the drug can be combined with other antiviral and symptomatic drugs.
Proproten-100, Anaferon, Tenoten, Afala, Colophort, Regaline, Impaza, Artrofon, Divaza, Afalaza, Tenoten for children, Anaferon for children
3 years. Do not use after the expiration date.
|Conditions of storage|
In the dark place at a temperature not exceeding 25 ° C. Keep out of reach of children.
Materiala Medica Holding, Russia
Materiala Medica Holding
Buy Ergoferon, tablets 20 pcs with delivery to USA, UK, Europe and over 120 other countries.